Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nordic Capital","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$846.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nordic Capital Acquires Advanz Pharma for $846 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Nordic Capital

    Menu

    Nordic Capital

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nordic Capital

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nordic Capital Acquires Advanz Pharma for $846 Million

              Details:

              Ceftobiprole medocaril, Zevtera, is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.

              Lead Product(s): Ceftobiprole Medocaril

              Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Advanz Pharma

              Deal Size: $846.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition June 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY